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option for maintenance of remission in ulcerative colitis, 
the picture in Crohn’s disease is variable. For maintenance 
of remission, key Cochrane systematic reviews have 
found conflicting results between the medical and surgical 
induced contexts. In this piece, the possible reasons for 
this are considered. It is proposed that clinicians should 
consider 5-aminosalicylates agents an option to maintain 
remission post-surgery. Future primary research is needed 
in the medical induced remission setting which considers 
the length of remission on enrolment and endoscopic 
or histological disease scores. Additionally, secondary 
research to rank the various treatment options in the 
post-surgical setting could be achieved through the use of 
network meta-analysis and will guide policy makers in the 
future.
Key words: 5-Aminosalicylate; Systematic review; Crohn’s 
disease; Inflammatory bowel disease; Cochrane
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This paper proposes that the varying length 
of remission and disease activity of patients enrolled in 
studies for medically induced remission is different to 
surgical induced remission and may explain differences 
in findings. This guides future research proposals. Future 
primary research is needed in the medical induced 
remission setting which considers the length of remission 
on enrolment and endoscopic or histological disease 
scores. Additionally, secondary research to rank the various 
treatment options in the post-surgical setting could be 
achieved through the use of network meta-analysis.
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Abstract 
5-Aminosalicylates are a class of anti-inflammatory agents 
that have been used for decades in inflammatory bowel 
disease. Whilst they are first line for induction and an 
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INTRODUCTION
There are broadly three classes of treatment that are 
commonly used to induce and maintain remission in 
inflammatory bowel disease (IBD): Antinflammatory 
agents, immunossupressive agents and biologic therapies. 
5-aminosalicylates (5-ASAs) are a group of antiinfla-
mmatory compounds used for many years to treat IBD. 
The first 5-ASA used in clinical practice was to manage 
arthritis in the 1940s[1]. It was noted that patients who 
had concomitant IBD had improvements in their bowel 
symptoms. 
COCHRANE EVIDENCE IN IBD
In the 1970s and 80s, there was growing academic and 
clinical concern with varying quality of primary research 
evidence and in particular reviews summarising evidence[2]. 
The concept of scientific medicine began to grow in 
response to this, which then became known as evidence 
based medicine[3]. The Cochrane Collaboration was at the 
forefront of evidence based medicine, leading the way in 
producing systematic reviews and methodological guidance 
for authors of reviews[4]. For 20 years, Cochrane has 
produced systematic reviews of primary research in human 
health care and health policy, and these are internationally 
recognized as the highest standard in evidence-based 
health care resources[5]. Whilst there have been criticisms of 
Cochrane reviews, they often inform international guidance 
and practice and so consideration of these reviews is vital 
for practising gastroenterologists.
WIDER COCHRANE EVIDENCE FOR 
5-ASA AGENTS IN IBD
This class of agents have been employed in a variety of 
formulations within the context of IBD. In ulcerative colitis, 
it is well excepted in international guidance[6] and from 
Cochrane systematic reviews of the topic[7] that 5-ASA 
preparations are effective in inducing remission. Similarly, 
they are shown to be effective within Cochrane systematic 
reviews for the maintenance of remission in ulcerative 
colitis[8] and suggested as first line therapy for maintaining 
remission[6].
Interestingly despite this widespread evidence for 
effectiveness in ulcerative colitis, in Crohn’s disease the 
evidence has always been more capricious. Early research 
demonstrated 5-ASAs are more effective for inducing 
remission in ileal, ileocolic, or colonic disease[9,10]. Due to 
this evidence, some 5-ASA agents have been frequently 
employed by gastroenterologists for mild Crohn’s disease. 
However, a Cochrane review updated in 2016[11] that 
highlights a small benefit over placebo, but inferiority to 
other agents for inducing remission and mixed findings 
in newer studies of higher 5-ASA dosing. Until further 
research is performed, the authors do not suggest their 
use. This is also reflected in international guidance that 
note the variability in the evidence and do not currently 
suggest their use[12,13]. 
CONFLICTING COCHRANE EVIDENCE IN 
MAINTAINING REMISSION IN CROHN’S 
DISEASE
For maintaining remission in Crohn’s disease, there is a 
significant difficulty in interpreting the Cochrane evidence. 
A recently published Cochrane review update[14] has found 
no evidence for the use of 5-ASA in maintaining medically 
induced remission. However, a review considering 5- 
ASA agents in post-surgical remission highlighted very 
different results[15]. 5-ASA was significantly more effective 
than placebo for averting relapses, with no statistical 
heterogeneity. A large number of subgroup analyses were 
completed to investigate length of follow up and dosage, 
with no change in the statistical significance of results, 
except when follow up was less than 12 mo. Clearly, this 
robust effectiveness result in the post-surgical setting[15] is 
at odds with the results for medically induced remission[14]. 
The only area of agreement between these two key 
reviews is related to occurrence of adverse events, with no 
statistical difference between 5-ASA and placebo.
The situation is further complicated in a complimentary 
review that investigates purine analogues for maintenance 
of post-surgical remission in Crohn’s disease[16]. Whilst 
these were effective against placebo, there were only two 
studies in this analysis. The majority of studies compared 
to 5-ASA, reflecting their widespread use in this context. 
Meta-analysis of five studies showed no difference in 
preventing clinically diagnosed relapse at 12-24 mo post-
surgery between 5-ASA and purine analogues. In fact, 
the trend in the risk ratio was towards 5-ASAs, suggesting 
inferiority of purine analogues. When considering adverse 
events that led to withdrawal of patients from treatment, 
these were statistically more common in the purine ana-
logue patients compared to 5-ASA. 
RECENT IMPACT ON PRACTICE 
GUIDANCE
As these key reviews[14-16] are reasonably contempor-
aneous, impact on international guidance is currently 
limited. However, UK guidance from the National Institute 
for Health and Care Excellence has recently reflected this 
evidence. Previous guidance clearly suggested the 5-ASA 
agents should not be recommended in the post-surgical 
settings[17], but the 2016 update now proposes 5-ASA can 
be offered[18] reflecting on this key Cochrane secondary 
evidence[15]. It remains to be seen whether other guidelines 
will shift advice in line with this evolving Cochrane evidence 
base.
UNDERSTANDING CONFLICTING 
RESULTS
The primary issue this spectrum of systematic review 
evidence raises is why 5-ASA agents have clear evidence 
of effectiveness in the post-surgical setting, but no 
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evidence in medically induced remission. There is no 
published research to give insight into these results, but 
the existing evidence base may hold the answer and allow 
hypotheses to be made.
Early evidence in Crohn’s disease suggested that 
more mild disease was susceptible to 5-ASA agents[9,10], 
particularly in terms of the location of disease. Whilst 
surgery within Crohn’s disease can be heterogeneous 
and is patient specific, it is long accepted that the 
most common indications relate to limited resections of 
particularly diseased areas with complications[19]. It is 
therefore possible that in the post-surgical setting, the 
patient has been reverted to a more disease naïve state 
within the remaining bowel, which due to pre-surgical 
medical management, is most commonly in a remission 
state. In many of the medical remission studies, this 
has been defined using clinical criteria and so at an 
endoscopic or histological level, there may well be disease 
activity. A counter view may suggest that because 
surgical patients had more severe disease, they do not 
have more mild disease. However, the author maintains 
that given the combination of surgical resection of these 
diseased areas and pre-surgical medical management, it 
is still likely that they represent a group with a different 
level of disease activity to the medical induce remission 
cohort of patients. This issue of clinical heterogeneity 
between the patient groups may explain why post-
surgery evidence demonstrates efficacy of 5-ASA agents.
This hypothesis also raises a related methodological 
issue. Whilst studies included in the Cochrane reviews[14-16] 
in both medically and surgically induced remission had to 
define remission using accepted international rating scales, 
the timing of entry appears particularly capricious within 
the medically induced remission papers[14]. A review of 
the characteristics of studies suggests that patients could 
have been in remission for up to two years on entry within 
these studies. This is in stark contrast to the post-surgical 
remission papers reviewed that required study entry within 
at the most 60 d of surgery[15,16]. When this is combined 
with the accepted limitations of clinical disease activity 
scoring[20] compared to endoscopic or histological scoring 
methods, it is entirely possible that patients entering both 
sets of studies were simply not at a similar state of disease 
activity. In terms of 5-ASA agents and the acceptance that 
they are particularly efficacious in mild disease, this is a vital 
issue to consider.
The final issue to be considered is in the context 
of the post-surgical setting when comparing 5-ASA to 
Purine analogues. For those who have considered the 
individual study data within the Cochrane review[16] it 
will be apparent that there is clearly a contrast between 
primary study conclusions of purine analogue efficacy and 
the meta-analysis performed. This is due to the intention 
to treat analysis performed in the review. A per protocol 
analysis would suggest superiority of purine analogues, in 
line with the individual studies. This is not the method used 
in the review for several Cochrane methodological reasons 
related to risk of bias from incomplete outcome data. 
Given the clearly pervasive problem with over a quarter 
of patients on purine analogues not able to continue due 
to side effects[16] this clearly demonstrates the limitations 
of per protocol analysis and supports this approach from 
Cochrane. This was worth comment as readers may have 
found this discrepancy concerning. The wider relevance of 
this intention to treat finding is to once again suggest that 
5-ASAs are not necessarily the most efficacious therapy 
in Crohn’s disease for either induction or maintenance of 
remission, but there is universal agreement on their good 
safety profile[7,8,11,14-16].
IMPLICATIONS FOR PRACTICE
Based on the current Cochrane systematic reviews, 5-ASA 
agents cannot be recommended for maintenance of 
medically induced remission. However, in the post-surgical 
remission setting they are safe and effective. Given the 
concerning safety profile of purine analogues, it is proposed 
that clinicians consider this when discussing options with 
patients for post-surgical medication to maintain remission.
IMPLICATIONS FOR RESEARCH 
There are two key areas that require further work. The 
first is within the medically induced remission setting. 
Given the volume of work suggesting the safety and 
potential efficacy, future large randomised controlled 
trials could be considered that pay particular attention to 
the extent and state of disease when entering the trial. 
Certainly, it is proposed that the use of endoscopic or 
histological methods to ensure induction of remission and 
consideration of the extent of previous disease are noted 
to ensure analysis can consider these factors that may be 
key in selecting appropriate patients for such therapy.
Secondly, given the most recent evidence now finds 
a role for 5-ASA agents in maintaining remission post-
surgery in Crohn’s disease, it is key to consider its relative 
efficacy to other agents, including immunosuppressive 
and biologic therapies. In the past, such analysis was 
impossible without individual primary trials investigating 
each comparison, but network meta-analysis offers 
this possibility[21]. This is a meta-analysis which allows 
multiple treatments to be compared directly and across 
trials using a common comparator, such as placebo. The 
end result of such analysis is to allow true conclusions 
to be drawn as to the relative efficacy and therefore 
shape future international guidance on such issues. The 
Cochrane Inflammatory Bowel Disease group is currently 
planning such a review.
CONCLUSION
It is proposed that clinicians should consider 5-ASA agents 
an option to maintain remission post-surgery, but evidence 
does not demonstrate similar efficacy in medically induced 
remission and so 5-ASA agents cannot be recommended 
in that context. Future primary research is needed in 
the medical induced remission setting which considers 
the length of remission on enrolment and endoscopic 
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